Cochrane · systematic review · CD007920
Anti‐vascular endothelial growth factor for neovascular glaucoma
Rittiphairoj, T, Roberti, G, Michelessi, M · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
4
No studies
1
Included studies
NR
No studies 1 · 16.7%Ungraded 1 · 16.7%Very low 2 · 33.3%Low 2 · 33.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyAnti‐VEGF versus no anti‐VEGF for neovascular glaucoma
Population: people with neovascular glaucoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of participants with IOP ≤ 21 mmHg, with or without ocular hypotensive medications, 4 to 6 weeks Anti‐VEGF vs no anti‐VEGF | RR 1.32 [1.1, 1.59] | 1 study · 93 participants | Low Downgraded: risk of bias, imprecision |
Mean IOP, 4 to 6 weeks Anti‐VEGF vs no anti‐VEGF | no estimate extracted | 3 studies · 173 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants with improvement in visual acuity of 2 ETDRS lines or 0.2 logMAR units, 4 to 6 weeks Anti‐VEGF vs no anti‐VEGF | RR 2.55 [1.6, 4.08] | 1 study · 93 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants with complete regression of new iris vessels, 4 to 6 weeks Anti‐VEGF vs no anti‐VEGF | RR 2.63 [1.65, 4.18] | 1 study · 93 participants | Low Downgraded: risk of bias, imprecision |
Proportion of participants with relief of pain and resolution of redness, 1 year Anti‐VEGF vs no anti‐VEGF | no estimate extracted | NR | No studies |
Proportion of participants with adverse events at various Anti‐VEGF vs no anti‐VEGF | no estimate extracted | 6 participants | Ungraded |
Anti‐VEGF medications compared with no anti‐VEGF medications for neovascular glaucoma
Population: people with neovascular glaucoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mean IOP 1 year Anti‐VEGF medications vs no anti‐VEGF medications | MD 1.4 | 2 studies · 70 participants | Low Downgraded: risk of bias, inconsistency |
Proportion of participants with IOP≤ 21 mmHg, with or without ocular hypotensive medications 1 year Anti‐VEGF medications vs no anti‐VEGF medications | no estimate extracted | 2 studies · 80 participants | Low Downgraded: risk of bias, inconsistency |
Proportion of participants with improvement in visual acuity of 2 ETDRS lines or 0.2 logMAR units 1 year Anti‐VEGF medications vs no anti‐VEGF medications | no estimate extracted | NR | No studies |
Proportion of participants with complete regression of new iris vessels various Anti‐VEGF medications vs no anti‐VEGF medications | no estimate extracted | 1 study · 40 participants | Low Downgraded: risk of bias, imprecision |
Proportion of participants with relief of pain and resolution of redness 1 year Anti‐VEGF medications vs no anti‐VEGF medications | no estimate extracted | NR | No studies |
Proportion of participants with adverse events various Anti‐VEGF medications vs no anti‐VEGF medications | no estimate extracted | 4 studies · 263 participants | Low Downgraded: imprecision, indirectness |